What are appropriate pain management options for a patient with chronic alcohol use disorder?

Pain Management in Patients with Alcohol Use Disorder

Prioritize non-opioid pharmacologic and nonpharmacologic therapies as first-line treatment, reserving opioids only for patients who fail these approaches and have low risk for misuse, with close monitoring and concurrent addiction treatment when needed.

First-Line Approach: Non-Opioid Medications

For patients with alcohol use disorder (AUD) and chronic pain, acetaminophen and NSAIDs should be your initial pharmacologic agents for musculoskeletal pain 1. However, critical caveats apply:

• Acetaminophen dosing must be reduced in patients with liver disease - use lower than the standard 4g/day given the hepatotoxic potential when combined with chronic alcohol use 1
• NSAIDs carry gastrointestinal bleeding risk, particularly problematic in patients with AUD; COX-2 selective agents reduce GI risk but increase cardiovascular risk 1

For Neuropathic Pain

Gabapentin is the recommended first-line agent for neuropathic pain, titrating to 2400mg daily in divided doses 1. This choice is particularly advantageous in AUD patients because:

• Gabapentin and pregabalin have demonstrated benefits in reducing alcohol cravings and extending time to relapse 2
• They provide dual benefit: pain management plus addiction support
• If gabapentin fails, consider serotonin-norepinephrine reuptake inhibitors or tricyclic antidepressants as second-line 1

Nonpharmacologic Interventions

Cognitive behavioral therapy is strongly recommended and should be integrated early 1. Additional evidence-based options include:

• Physical and occupational therapy 1
• Yoga for neck/back pain, headache, and musculoskeletal pain 1
• Hypnosis for neuropathic pain 1

When Opioids Become Necessary

Opioids should never be first-line agents in patients with AUD 1. The 2016 CDC guidelines and multiple pain management guidelines emphasize that opioid therapy should only be considered when:

1. Non-opioid therapies have failed
2. Expected benefits for pain AND function outweigh risks
3. The patient reports moderate to severe pain with functional impairment 1, 3, 4

Critical Safety Framework for Opioid Use

If opioids are deemed necessary after exhausting alternatives:

Start with the lowest effective dose of immediate-release formulations 3, 5:

• Begin with short-acting opioids PRN to establish effective dosing
• Avoid extended-release/long-acting opioids initially 3
• Use caution at any dosage, carefully reassess when reaching 50 MME/day, and avoid or justify doses ≥90 MME/day 3

Mandatory concurrent interventions 3, 4:

• Review prescription drug monitoring program (PDMP) data before starting and every 1-3 months
• Urine drug testing before initiation and at least annually
• Establish clear treatment goals and discontinuation criteria upfront
• Evaluate benefits and harms within 1-4 weeks of starting, then every 3 months minimum

Prescribe naloxone when opioids are used in patients with substance use history, as they are at increased overdose risk 4

Special Consideration: Patients on Medication-Assisted Treatment

For patients already receiving methadone or buprenorphine for AUD:

Methadone patients: Split dosing into 6-8 hour intervals extends analgesic effects; add 5-10% of current dose as afternoon/evening doses for pain control 1. If additional methadone isn't feasible, add pain-specific medications (gabapentin for neuropathic pain, NSAIDs for musculoskeletal pain) 1

Buprenorphine patients: Increase buprenorphine in divided doses (4-16mg every 8 hours) as initial step 1. If maximal buprenorphine doses fail, add long-acting potent opioids like fentanyl, morphine, or hydromorphone - higher doses may be needed due to buprenorphine's high receptor binding affinity 1

Absolute Contraindications and Drug Interactions

Never combine opioids with benzodiazepines - this dramatically increases overdose risk 3, 4

Be aware of critical alcohol-medication interactions 2:

• Acetaminophen + alcohol = hepatotoxicity
• NSAIDs + alcohol = increased GI bleeding
• Consider interactions with disulfiram or naltrexone if patient is receiving these for AUD treatment

Collaborative Care Requirements

Patients with co-occurring pain and AUD require integrated treatment 6, 7. When prescribing opioids:

• Collaborate with addiction specialists, pain specialists, or palliative care 5
• Ensure concurrent addiction treatment is optimized - offer medication-assisted treatment (buprenorphine or methadone) combined with behavioral therapies 3
• Communicate with opioid treatment programs if patient is enrolled; obtain signed release for information exchange 1

Mental Health Screening

Screen all patients for depression using two questions: "During the past 2 weeks have you been bothered by feeling down, depressed, or hopeless?" and "During the past 2 weeks have you been bothered by little interest or pleasure in doing things?" 1. If positive, use PHQ-9 for further assessment; scores ≥10 warrant psychiatric referral 1

Bottom Line Algorithm

1. Start with acetaminophen (reduced dose if liver disease) or NSAIDs for musculoskeletal pain; gabapentin for neuropathic pain
2. Add nonpharmacologic therapies (CBT, physical therapy, yoga)
3. Only if steps 1-2 fail AND patient has moderate-severe pain with functional impairment: Consider time-limited opioid trial with lowest effective dose, immediate-release formulations, PDMP monitoring, urine drug testing, naloxone prescription, and addiction specialist collaboration
4. Treat both conditions concurrently - pain management should never occur in isolation from addiction treatment 6, 7